Evaluation of early-phase <sup>18</sup>F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with <sup>18</sup>F-FDG PET at group and single patient level.

J Alzheimers Dis · 2025 · PMC12231879 · PMID 40340729

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although FDG PET performed slightly better in ROC analyses, this difference did not reach statistical significance, as confirmed by the DeLong test.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Evaluation of early-phase &lt;sup&gt;18&lt;/sup&gt;F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with &lt;sup&gt;18&lt;/sup&gt;F-FDG PET at group and single patient level.

The sentences

Evaluation of early-phase <sup>18</sup>F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with <sup>18</sup>F-FDG PET at group and single patient level.